The Remote Patient Monitoring Battle CVS Won't Talk About

UnitedHealth Group and CVS Health are fighting CMS's proposed Medicare restrictions on remote patient monitoring to protect a multibillion-dollar revenue stream and keep RPM services alive for vulnerable Australians and Americans alike.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.

Why CMS Wants to Curb Rpm in Health Care

In July 2024, CMS released a proposal that could cut up to $2 billion of RPM payments each year. The agency says the rules are needed to stop billing for token interactions that barely meet the definition of medically necessary remote monitoring. In my experience around the country, I’ve seen providers struggle to prove that a brief data upload counts as a full-blown service.

CMS’s chief concern is fraud. Devices can be shipped to patients, data can sit idle, and providers can still claim a CPT 99457 or 99458 code for a five-minute review. The agency argues that this creates a lucrative, low-effort billing stream that diverts funds from genuine chronic-care management. The proposal also reflects alarm at the rapid, billion-dollar growth of the RPM market, which CMS believes may be outpacing its ability to audit.

• Billing without active management: CMS says many claims lack documented clinical decisions.
• Device misuse: Some vendors ship equipment but never train patients, yet still bill.
• Fee-for-service mismatch: RPM’s per-patient revenue threatens the traditional Medicare payment model.

From my reporting, the ripple effect could be severe. Small primary-care clinics that rely on RPM to monitor heart failure or diabetes may lose the financial incentive to offer these services. Larger health systems, with the capital to absorb a reduced reimbursement rate, would dominate the market.

Key Takeaways

• CMS aims to slash up to $2 billion in RPM payments.
• Fraud risk is the headline driver of the proposal.
• Small providers could lose RPM revenue quickly.
• Large health systems stand to benefit from tighter rules.
• Patients may face reduced access to remote chronic care.

How UnitedHealth and CVS Formally Pushed Back

When the proposal landed on the desk of policymakers, UnitedHealth Group and CVS Health fired off formal comment letters that were as detailed as they were defiant. I sat down with the public filings and, fair dinkum, the arguments were strikingly similar.

UnitedHealth argued that limiting RPM to “established patients” would leave the most vulnerable - those who bounce between urgent-care centres, community clinics, and home-care agencies - without a safety net. In the comment, UnitedHealth quoted internal data showing a 12-point drop in hospitalisations for members with chronic heart disease when RPM was applied early, before they became “established”. CVS Health, on the other hand, warned that the rule would stifle the innovation pipeline that underpins its Aetna-run value-based contracts. The retailer highlighted a pilot in New York where RPM reduced emergency-department visits for COPD by 18 per cent, saving roughly $4 million in Medicare-eligible costs.

Both giants presented the same set of evidence: RPM works, it saves money, and the proposed limits would undo those gains. Their letters also pointed out that state-level health-equity programmes - many of which fund RPM for low-income patients - would be undercut, creating a patchwork of access that favours private insurers over public health.

1. UnitedHealth’s equity argument: RPM should reach patients before they become “established”.
2. CVS’s innovation claim: RPM is a cornerstone of Aetna’s value-based care pilots.
3. Data point: 12-point drop in hospitalisations for heart disease members.
4. Data point: 18% reduction in COPD ED visits in a New York pilot.
5. Financial impact: $4 million saved in Medicare-eligible costs.

These arguments were not just lofty rhetoric; they were backed by the same UnitedHealth, CVS push back on Medicare plan to curb remote patient monitoring - STAT. The letters have already sparked a flurry of media coverage and, as I’ve seen in conversations with policy analysts, the battle lines are being drawn well before the 2025 Physician Fee Schedule is finalised.

The Hidden Threat to Remote Patient Monitoring Reimbursement Rates

Look, the biggest danger isn’t a blanket ban - it’s the tightening of the CPT codes that make RPM financially viable. The current model relies on two main codes: CPT 99457 for 20 minutes of clinical staff time reviewing data, and CPT 99458 for each additional 20-minute increment. If CMS narrows the circumstances under which these codes can be billed - for example, requiring a face-to-face visit in the prior 30 days - the economics shift dramatically.

To illustrate, here’s a simple table that shows the current average reimbursement versus a hypothetical reduced-rate scenario:

That $25-$20 cut per code may look small, but when you multiply it by thousands of patients, the return on investment evaporates. Small clinics that spend $300-$500 per patient on devices, training, and platform licences will find the margin razor-thin, pushing them either out of the market or into partnerships with the very giants that are lobbying against the rule.

What’s more, the proposed rule adds a “active management” clause - providers must document a specific clinical decision for every data transmission. That adds documentation labour, which translates into higher staffing costs. In my experience, these hidden costs are the Achilles’ heel of any RPM rollout that isn’t backed by deep cash reserves.

• Reduced CPT rates: $25-$20 less per code.
• Increased documentation burden: Every 20-minute review must link to a care plan change.
• Device cost pressure: $300-$500 per patient upfront.
• Scale advantage: Large health systems can absorb the hit, independents cannot.
• Vendor squeeze: Smaller tech firms risk being priced out.

In short, the policy could turn RPM from a growth engine into a niche service offered only by the biggest players - UnitedHealth, CVS, Kaiser - leaving the rest to watch from the sidelines.

What Is Medicare RPM’s Real Future After This Fight?

Here’s the thing: the final 2025 rule will probably be a compromise, but the negotiation itself will cement a new reality for RPM. Instead of being a flexible, clinician-driven tool, it will become a tightly defined benefit with hard-wired eligibility, device, and data-review thresholds.

When I talk to health-system CEOs across Melbourne, Sydney, and Brisbane, the consensus is clear - they are already modelling two scenarios. Scenario A is a “locked-down fee-for-service” world where only patients who meet the strictest CMS criteria generate revenue. Scenario B is a “value-based carve-out” where RPM is bundled into alternative payment models (APMs) such as accountable care organisations or state-run chronic-care contracts.

UnitedHealth and CVS have a head start in Scenario B. Their contracts already embed RPM into Aetna’s value-based arrangements and CVS’s retail-clinic partnerships, meaning they can shift the revenue stream away from Medicare fee-for-service and into risk-sharing deals. Smaller providers will either need to join a larger APM or negotiate their own private-payer contracts.

1. Scenario A - fee-for-service: Strict CMS definitions, lower reimbursement, high documentation load.
2. Scenario B - value-based carve-out: RPM bundled into risk-share agreements, potentially higher total payments.
3. Key difference: Who owns the data and who decides the care pathway.
4. Strategic move: Align with insurers that already run APMs.
5. Risk: Getting locked into a low-rate Medicare model.

If the rule ends up codifying a narrow definition, the market will pivot toward private contracts, and that is exactly where UnitedHealth and CVS have poured millions of dollars into lobbying. The “what is RPM in health care” question will be answered by payer policy, not by clinicians.

Three Actions for Providers Amid the RPM Policy War

Here’s a practical checklist I put together after weeks of interviewing compliance officers, clinicians, and health-tech entrepreneurs. If you want to stay afloat, start now.

1. Audit your RPM panels: Pull a report of every patient billed under CPT 99457/99458 in the past 12 months. Verify that each claim includes documented clinical decisions, timestamps, and evidence that the patient is an “established” beneficiary under the proposed rule.
2. Diversify revenue streams: Approach private insurers, state Medicaid programmes, and even employer-sponsored health plans about value-based contracts that pay per outcome rather than per code. Many of these entities are already looking for RPM-enabled chronic-care solutions.
3. Upgrade documentation workflows: Use integrated EHR alerts that prompt clinicians to log a care-plan modification each time they review data. This turns passive data collection into billable chronic-care management.
4. Engage with vendors: Negotiate device-as-a-service deals that spread capital costs over longer periods, reducing upfront cash outlay.
5. Educate patients: Provide clear, written instructions on how to use devices and why regular transmissions matter. A well-informed patient reduces the risk of a “no-use” audit finding.
6. Monitor policy updates: Set up a quarterly review of CMS releases and any new guidance from Medicare Administrative Contractors (MACs). Early awareness can save you from retroactive penalties.

By taking these steps, you not only protect your bottom line but also keep the promise of RPM - timely, data-driven care for chronic disease - alive for the patients who need it most.

FAQ

Q: What exactly is Medicare RPM?

A: Medicare Remote Patient Monitoring (RPM) allows clinicians to bill for collecting and reviewing health data from patients at home, using CPT codes 99457 and 99458. The service must involve active management and a documented care decision for each transmission.

Q: How will the proposed CMS changes affect small clinics?

A: The changes could lower reimbursement rates and add stricter eligibility rules, making it harder for small practices to cover device costs and documentation labour. Many may need to join larger networks or shift to private-payer contracts.

Q: Why are UnitedHealth and CVS fighting the rule?

A: Both companies run large-scale RPM programmes that generate billions in revenue. Restricting billing would cut their earnings and give an advantage to smaller, less-integrated competitors, so they are lobbying to keep the current payment structure.

Q: Can providers still use RPM under a value-based contract?

A: Yes. Many insurers already bundle RPM into risk-share agreements, which can sidestep Medicare fee-for-service limits. This approach can provide more stable revenue if the provider meets quality metrics.

Q: What should I do right now to prepare?

A: Start an audit of all RPM claims, tighten your documentation to show active management, and explore alternative payer contracts. Early action will reduce the risk of audit findings once the final rule is published.